Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Gains from Investment Securities (2022 - 2025)

Gossamer Bio (GOSS) has 2 years of Gains from Investment Securities data on record, last reported at $5.9 million in Q4 2024.

  • For Q4 2024, Gains from Investment Securities changed N/A year-over-year to $5.9 million; the TTM value through Sep 2025 reached $5.9 million, up 1053.14%, while the annual FY2024 figure was $5.3 million, N/A changed from the prior year.
  • Gains from Investment Securities reached $5.9 million in Q4 2024 per GOSS's latest filing, up from -$305000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.9 million in Q4 2024 and bottomed at -$3.0 million in Q3 2022.